Overview

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Infigratinib